α-Glucosidase-IN-18 (7B) is an orally active inhibitor of α-glucosidase, displaying an IC 50 value of 3.96 μM. This compound exhibits antidiabetic properties [1].

α-Glucosidase-IN-18 (7B) (p.o., 10 or 20 mg/kg) has antidiabetic activity and significantly reduces blood glucose levels, from 392.16 mg/dL of diabetic control to 112.97 mg/dL at a concentration of 20 mg/kg after 28 days, while effectively slowing weight loss due to diabetes in male Wistar albino rats with streptozotocin-induced diabetes [1]. α-Glucosidase-IN-18 (7B) (p.o., 10 or 20 mg/kg) had an anti-hyperlipidemic effect with total CH levels from 226.03 mg/dL in the diabetic control to 136.4 mg/dL, LDL levels from 183.3 mg/dL to 114.18 mg/dL and TG levels from 189.35 mg/dL to 118.61 mg/dL in male Wistar albino rats with streptozotocin-induced diabetes [1]. α-Glucosidase-IN-18 (7B) decreases ALP levels from 3.01 mg/dL to 0.85 mg/dL and 0.79 mg/dL, SGPT levels from 59.43 mg/dL to 27.07 mg/dL and 23.91 mg/dL, SGOT levels from 49.67 mg/dL to 26.71 mg/dL and 23.08 mg/dL, serum creatinine from 3.01 mg/dL to 0.85 mg/dL and 0.79 mg/dL, and insulin levels from 0.369 mg/dL to 0.621 mg/dL and 0.639 mg/dL, respectively at doses of 10 and 20 mg/kg in male Wistar albino rats with streptozotocin-induced diabetes [1].